Common allegations regarding Effexor have led the US Judicial Panel on multidistrict litigation to transfer Effexor lawsuits to the Eastern District of Pennsylvania.
Effexor is an SNRI (serotonin-norepinephrine reuptake inhibitor). It is also known as Venlafaxine or Efexor. It was first introduced by Wyeth, but now marketed by Pfizer, who purchased Wyeth in 2009. In 2007, it was the 6th most commonly described antidepressant in the US, with 17.2 million prescriptions.
Cases are joined into multidistrict litigation when they have common questions of fact, to avoid repetition during discovery and pre-trial proceedings. The lawsuits against the makers of Effexor allege that patients were not adequately warned about risks to infants, birth defects, including an increased risk of congenital heart defects, persistent pulmonary hypertension (PPHN), and oral clefts.
Scientists are also looking into whether exposure to SSRIs like Zoloft,or SNRIs like Effexor may contribute to developmental problems, including autism spectrum disorder.